Patent ID: 11884725
Assignee: AMPSOURCE BIOPHARMA SHANGHAI INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 3:
4. The antibody or the antigen-binding fragment thereof according to claim 1, comprising:
(1) CDRs defined by the IMGT numbering system:
(1a) following three heavy chain variable region (VH) CDRs:
(i) CDR-H1, consisting of a sequence as shown by SEQ ID NO: 18, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 18;
(ii) CDR-H2, consisting of a sequence as shown by SEQ ID NO: 19, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 19; and
(iii) CDR-H3, consisting of a sequence as shown by SEQ ID NO: 20, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 20; and/or
(1b) following three light chain variable region (VL) CDRs:
(iv) CDR-L1, consisting of a sequence as shown by SEQ ID NO: 27, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 27;
(v) CDR-L2, consisting of a sequence as shown by SEQ ID NO: 25, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 25; and
(vi) CDR-L3, consisting of a sequence as shown by SEQ ID NO: 23, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 23; or
(2) CDRs defined by the Chothia numbering system:
(2a) following three heavy chain variable region (VH) CDRs:
(i) CDR-H1, consisting of a sequence as shown by SEQ ID NO: 16, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 16;
(ii) CDR-H2, consisting of a sequence as shown by SEQ ID NO: 17, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 17; and
(iii) CDR-H3, consisting of a sequence as shown by SEQ ID NO: 15, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 15; and/or
(2b) following three light chain variable region (VL) CDRs:
(iv) CDR-L1, consisting of a sequence as shown by SEQ ID NO: 24, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 24;
(v) CDR-L2, consisting of a sequence as shown by SEQ ID NO: 25, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 25; and
(vi) CDR-L3, consisting of a sequence as shown by SEQ ID NO: 26, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 26; or
(3) CDRs defined by the Kabat numbering system:
(3a) following three heavy chain variable region (VH) CDRs:
(i) CDR-H1, consisting of a sequence as shown by SEQ ID NO: 13, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 13;
(ii) CDR-H2, consisting of a sequence as shown by SEQ ID NO: 14, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 14; and
(iii) CDR-H3, consisting of a sequence as shown by SEQ ID NO: 15, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 15; and/or
(3b) following three light chain variable region (VL) CDRs:
(iv) CDR-L1, consisting of a sequence as shown by SEQ ID NO: 21, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 21;
(v) CDR-L2, consisting of a sequence as shown by SEQ ID NO: 22, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 22; and
(vi) CDR-L3, consisting of a sequence as shown by SEQ ID NO: 23, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 23; or
(4) CDRs defined by the Kabat numbering system:
(4a) following three heavy chain variable region (VH) CDRs:
(i) CDR-H1, consisting of a sequence as shown by SEQ ID NO: 13, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 13;
(ii) CDR-H2, consisting of a sequence as shown by SEQ ID NO: 28, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 28; and
(iii) CDR-H3, consisting of a sequence as shown by SEQ ID NO: 15, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 15; and/or
(4b) following three light chain variable regions (VL) CDRs:
(iv) CDR-L1, consisting of a sequence as shown by SEQ ID NO: 29, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 29;
(v) CDR-L2, consisting of a sequence as shown by SEQ ID NO: 30, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 30; and
(vi) CDR-L3, consisting of a sequence as shown by SEQ ID NO: 23, or a sequence with one or more substitutions, deletions or additions relative to the sequence as shown by SEQ ID NO: 23;
wherein, the substitutions in any one of (i) to (vi) are conservative substitutions.